View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
May 5, 2021

Bharat prepares interim Phase I data for intranasal Covid-19 vaccine; reveal planned this month, investigator says

Bharat Biotech is reviewing interim safety and immunogenicity data from a Phase I trial investigating its intranasal Covid-19 vaccine BBV154, with results planned for release this month, said Dr David Curiel, director, Biologics Therapeutics Centre, Washington University School of Medicine, St Louis.

By Reynald Castañeda

Bharat Biotech is reviewing interim safety and immunogenicity data from a Phase I trial investigating its intranasal Covid-19 vaccine BBV154, with results planned for release this month, said Dr David Curiel, director, Biologics Therapeutics Centre, Washington University School of Medicine, St Louis. The data will cover information from around 30 participants who have received the single-dose, simian adenovirus-vectored vaccine some two months after administration, added Curiel, who codeveloped the vaccine and is involved in the analysis.

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

The analysis of the data in India has been done, with data cross check ongoing in the US, Curiel noted. Immunogenicity titers triggered by BBV154 will be compared with other Covid-19 vaccines already authorised, he added. The Phase I has a primary endpoint looking into safety and reactogenicity, with secondary endpoints looking into humoral and immune responses. An interim analysis will be performed at day 42, with data submitted to India’s Central Drugs Standard Control Organisation (CDSCO). The trial was approved in India in the first week of March.

On 23 September, Bharat locked in a licensing agreement with the Washington University School of Medicine for BBV154. Hyderabad, India-based Bharat owns the rights to distribute the vaccine in all markets except for the US, Japan and Europe. Curiel is one of the founders of Precision Virologics, which owns the rights in these territories. Bharat did not respond to a request for comment.

The Phase I’s 175 participants are divided into three groups. In group one, 70 volunteers will receive the single-dose vaccine on day 0 and a placebo on day 28. Meanwhile, 70 participants in group two will receive two doses of the vaccine with a 28-day gap. Some 35 participants in group 3 will receive placebo in both doses.  Phase I is listed as having completed recruitment on the India Clinical Trials Registry website. Curiel said the country has a tight network of nurse practitioners, which makes recruiting participants straightforward.

At present, it is being discussed if single-dose BBV154 would require a booster dose to address variants of concern (VOCs), Curiel said. B.1.351, the VOC first discovered in South Africa, is being considered, he added. BBV154 features the spike protein from the original SARS-CoV-2 virus.

All eyes are on India with daily new Covid-19 cases breaking records, with local healthcare resources reaching a breaking point. India’s daily infection rates recently peaked on 31 April with 401,993 cases, while 357,316 new cases were reported yesterday (3 May), according to the Johns Hopkins Coronavirus Resource Centre. This is a significant jump from lows of around 9,000 daily new cases in February.

In January, Bharat’s other Covid-19 vaccine, Covaxin, drew international headlines when it secured emergency use authorisation in India under what was called “clinical trial mode.” This authorisation was due to the vaccine only having safety and immunogenicity data. Covaxin features an inactivated SARS-CoV-2 virus.

On 1 May, India opened Covid-19 vaccine use to people ages 18 years and above, though vaccine shortages in the country are widely reported. Serum Institute of India’s Covishield (SII-ChAdOx1 nCoV-19) and Russia’s Sputnik V, both adenovirus-vectored vaccines, are the two other Covid-19 vaccines authorised in India.

Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena